# enGene Therapeutics Inc. (ENGN): MoatMap facts

As of 13 Nov 2026. Research data, not investment advice.

As of 13 Nov 2026, the MoatMap Score for enGene Therapeutics Inc. (ENGN) is 13/100, ranked against 25,000+ stocks in 38 markets (Quality 25, Value 35, Momentum 30, each scored against its sector).

- MoatMap Score: 13/100, a percentile across 25,000+ stocks in 38 markets (100 is best).
- Quality 25, Value 35, Momentum 30: each a 0-100 percentile within Healthcare.
- Position: #23,156 overall, #2,137 in Healthcare.
- Listing: United States, NCM; Healthcare / Biotechnology.
- Last close: 2.28 USD on 12 Nov 2026.
- Insider filings, last 180 days: directors bought USD 10K.

Source: https://moatmap.ai/stock/ENGN
How the scores work: https://moatmap.ai/methodology
Does the score work? Each tenth of the ranking is tracked monthly: https://moatmap.ai/decile-tracker